Fig. 2

CTC gene expression signature, including STAT3, PRKCB, and CDK6, effectively stratify patients treated with CDK4/6 inhibitors plus endocrine therapy into responders and non responders. A Receiver operating characteristic (ROC) curve for the signature including the indicated genes at visit 1 to classify patients' therapy response, achieving an AUC of one for cohort 1 (n = 21, 5 non responders vs 16 responders). B Confusion matrix showing the accuracy of the prediction model for cohort 2 (n = 12, one non responder vs 11 responders). C ROC curve for the same signature, which successfully categorized patients according to their therapeutic response at visit 1 for cohort 3 with an AUC of 0.84 (n = 16, seven non responders vs nine responders). D Confusion matrix showing the accuracy of the prediction model for cohort 3 (n = 16, seven non responders vs nine responders)